The corporate selected is having status as amalgamated hence financial data is not available. You may check its last filed documents by making a request.
About
Basic Data Updated:
1 month agoIndustry
Company Details
- Location
Bangalore, Karnataka, India
- Website12224421
- Telephone12224421
- Email Address12224421
- Social Media12224421
| CIN/LLPIN/FCRN | U24231KA2002PLC030643 |
| Company No. | 030643 |
| Company Classification | Public Limited Indian Non-Government Company |
| Incorporation Date | 17 Jun 2002 |
| Date of AGM | 25 Jul 2013 |
| Date of Balance Sheet | 31 Mar 2013 |
| Listing Status | Unlisted |
| ROC Code | Roc Bangalore |
Financials of Biocon Biopharmaceuticals Limited
Enhance accessibility to Biocon Biopharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
Corporate Structure
Unlock access to Biocon Biopharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
People in Biocon Biopharmaceuticals Limited
Unlock and access historical data on people associated with Biocon Biopharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Executive Team (2)
Kiran Shaw
Managing DirectorAppointment Date: 17-Jun-2002
Status: Current
SB
Sridevi Bhamidipati Company SecretaryStatus: Current
Board Members(3)
Charges (Loans)
There are no open charges registered against the company as per our records.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Biocon Biopharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Biocon Biopharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alert
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
Related Corporates (Common Directorship)
8 years 7 months 
Recent activity within the organization
Annual General Meeting
Biocon Biopharmaceuticals Limited last Annual general meeting of members was held on 25 Jul 2013 as per latest MCA records.
25 Jul 2013Balance Sheet
Biocon Biopharmaceuticals Limited has filed its annual Financial statements for the year ended 31 Mar 2013 with Roc Bangalore.
31 Mar 2013Director Appointment
Arun Suresh Chandavarkar was appointed as a Nominee Director was appointed as a Nominee Director on 22 Mar 2007 & has been associated with this company since 17 years 2 months .
22 Mar 2007Director Appointment
Chinappa Muckatira Bhemaiah was appointed as a Alternate Director was appointed as a Alternate Director on 22 Mar 2007 & has been associated with this company since 17 years 2 months .
22 Mar 2007Director Appointment
John Mccallum Marshall Shaw was appointed as a Director was appointed as a Director on 17 Jun 2002 & has been associated with this company since 22 years .
17 Jun 2002
Recent News, Updates & Announcement
- Biocon sells 996 stake in contract research firm Syngene via open market.
Business Standard 01 Feb 2023
- European Medicines Agency Accepts Marketing Authorization Applications for Mylan and Biocons Proposed Biosimilars Trastuzumab and Pegfilgrastim.
PRNewswire Mylan NV NASDAQ TASE MYL and Biocon Ltd BSE code 532523 NSE BIOCON today announced that the European Medicines Agency EMA has.
PR Newswire 30 Nov 2017
Frequently asked questions
What is the Incorporation or founding date of Biocon Biopharmaceuticals Limited?
